BioSpace News Archive

Business

Novelion to Cut an Unknown Number of Jobs in Restructuring

Novelion will slash an unknown number of jobs as it initiates “significant cost reduction plans.”

January 26, 2018
·
2 min read
·
Alex Keown
BioCapital

Incoming Novartis CEO, Bayer Leader Join President Trump for Private Dinner at Davos

During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.

January 26, 2018
·
2 min read
·
Alex Keown
Business

Kalytera Announces Issuance of Shares Under Services Agreement With The Salzman Group of Israel

Under the deal, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.

January 26, 2018
·
3 min read
AmoyDx’s Plasmid Diagnostic for EGFR Mutations Approved in China

Last year, AmoyDx’s EGFR diagnostic was approved for use in the EU.

January 26, 2018
·
1 min read
BioStem Technologies Announces the Engagement of Investment Banking Firm Young America Capital for $15M 06(c) Offering

The $15 million offering will be open not only to individual accredited investors, but also to qualified institutional buyers.

January 26, 2018
·
3 min read
Business

LexaGene Names Greg Dale VP of Product Development and Manufacturing

This follows the recent completion of LexaGene’s prototype assembly for what will be the world’s first fully automated, open-access pathogen detection system, which will be used across the food safety, veterinary and human clinical diagnostics industries.

January 26, 2018
·
4 min read
Deals

M&A Fury Hits and It’s Only Just January

We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.

January 26, 2018
·
1 min read
Drug Development

Solid Biosciences Discloses DMD Trial Setback Amid $125M IPO Push

The surprising disclosure was outlined in a November 2017 letter from the FDA.

January 26, 2018
·
3 min read
·
Mark Terry
Biotech Bay

Why Bay Area’s XOMA Surged 700% in 2017 by Not Making Drugs

The company burned through $1.2B and never brought a drug to market in its 37 years.

January 26, 2018
·
4 min read
·
Mark Terry
Deals

J&J Bows Out of Race for Pfizer’s $20B Consumer Health Biz

Now insiders say J&J has decided it is no longer interested.

January 26, 2018
·
2 min read
·
Mark Terry